• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines

    KemPharm Receives $10M Milestone for FDA Approval of Azstarys

    Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax

    Syneos, Medable Partner for New Decentralized Capabilities

    CSafe Global Appoints SVP of Technology and Innovation
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Evotec to Build Second Biologics Mfg. Facility in Toulouse

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    TraceLink Introduces Opus Platform

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines

    KemPharm Receives $10M Milestone for FDA Approval of Azstarys

    Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax

    Syneos, Medable Partner for New Decentralized Capabilities

    Valneva’s Inactivated, Adjuvanted COVID-19 Vax Achieves Positive Data
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Unifying Quality Manufacturing to Drive Speed, Collaboration, and Compliance

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Quotient Sciences

    Syngene

    PCI Pharma Services

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Baxter BioPharma Solutions

    Reed-Lane

    Quotient Sciences

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Contract Manufacturing Budget Trends

    Study shows where the money is, and isn’t, flowing

    Related CONTENT
    • Lessons Learned: Choosing and Managing a CDMO
    • The Ever-Evolving World of Combination Products
    • Embedding Your Drug Strategy Within a Solid Foundation for Success
    • Sepha Launches Small Batch Contract Packaging Service
    • A Potential “Marriage”
    Eric S. Langer, BioPlan Associates07.12.16
    Contract manufacturing organizations (CMOs) should brace themselves for more competition this year as the tide of spending on outsourced manufacturing appears to be slowing down. That’s according to results from BioPlan Associates’ 13th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production. In this year’s study, we examine, among many aspects of the industry, budget trends within biomanufacturing.

    Biomanufacturers’ outsourcing budgets have enjoyed a rebound in recent years, swinging from a contraction in funding in the recessionary years, to hikes averaging close to 4% over the past 2 years. In 2016, things seem to be changing. Based on our survey of 222 qualified individuals at biopharmaceutical manufacturing facilities, we estimate that budgets for outsourced biopharmaceutical manufacturing will increase by an average of just 2.4% this year. That’s the lowest increase of the 12 industry areas we measured, below the next-lowest (new facility construction, 3.5%), and less than one-third of the growth anticipated in new capital equipment spending (of 7.9%).

    What’s interesting to see is that the proportion of manufacturers expecting to increase their outsourcing budgets has not dipped appreciably. This year, roughly 36% of respondents plan to hike their outsourcing budgets, relatively on par with last year’s 39% and 2014’s 37%. This suggests that the magnitude that budgets are growing is on the decline. In other words, manufacturers who may have upped their outsourcing spending by 10, 20% or even more over the past couple of years might now be tempering that growth. Alternatively, those same manufacturers might be in the process of being replaced by others whose budgets had remained flat but are now inching up.

    Neither of these scenarios is bleak for CMOs in and of themselves. But they are an interesting development in light of other budget trends identified in our study. Chief among those is a positive shift in budget growth for in-house biopharmaceutical manufacturing. Whereas budget growth had been on the decline for in-house manufacturing—down to a 2.8% projected increase last year—it has jumped this year to an estimated 4.9% increase. 

    Together, these trends signal a budget shift from outsourcing, to in-house manufacturing, which may be a more worrisome trend for CMOs if it remains over a sustained period.

    It isn’t all bad news, though. While budget growth for outsourced biomanufacturing may be declining, the slack may be picked up by spending on outsourcing of other aspects including R&D. Separately in our survey we asked biomanufacturers to estimate their change in spending on outsourcing of R&D or manufacturing in the next 12 months. We found that 56.5% are planning an increase of some degree, the largest proportion in at least the past 5 years. In fact, almost 1 in 10 respondents intend to increase their spending in these areas by more than 50%. The resultant average increase in spending on outsourcing of R&D or manufacturing—of 14%—is above last year’s estimated increase of 13%, and also trends higher than 2014 (13.5%) and 2013 (10.4%).

    In combination with the data showing a slowdown in outsourcing budgets, our study results suggest that outsourcing budgets may be shifting away from manufacturing and towards R&D.

    What do budget trends mean for CMOs?
    This year’s budget results showing lower spending growth on outsourced biomanufacturing may portend increased competition among CMOs. This in turn may flatten the recent price increases for CMO services, as contract manufacturers compete for business.

    There are signs that clients are looking to outsource in order to cut costs, meaning that pricing might be a bigger issue for them than in recent years, if CMOs are to convert additional in-house processes to outsourced operations. And some of these operations will be increasingly going offshore. According to our survey, almost 1 in 5 (18%) biopharmaceutical manufacturers last year outsourced manufacturing to non-domestic service providers specifically to cut costs. That continues a general trend in offshoring to cut costs, up from 14.3% last year and triple the percentage from 2011 (5.7%).

    Meanwhile, this year one-sixth of respondents (16.7%) report having outsourced manufacturing to domestic service providers in the prior 12 months as a cost-cutting mechanism. As with offshoring, this marks another increase, up from 14.9% last year and more than double the proportion from 2011 (7.1%).

    These increases are again interesting in light of other data showing that outsourcing of jobs as a cost-cutting mechanism is either flat or receding. It seems that the pendulum is swinging away from outsourcing jobs to outsourcing manufacturing in order to cut costs. Nevertheless, the implication for CMOs is that pricing may become a more pressing part of the outsourcing decision calculation.

    Separate results from our study suggest that it already is an important factor. We asked biotherapeutic developers to rate the importance of various factors when considering outsourcing manufacturing to a CMO. We found exactly 8 in 10 saying that it was “important” or “very important” that CMOs demonstrate the cost effectiveness of their services. While this figure has not changed in recent years, relatively speaking, cost-effectiveness is becoming more important.

    Demonstrating cost-effectiveness of services is now the 7th-most important issue for clients of the 19 identified issues. Pricing was the 8th-most important last year and the 10th-most important the year before. As such, pricing seems to be gradually rising the ranks when it comes to the issues that matter to clients.

    Of course it is not the most important one. Instead, with competition potentially rising for outsourcing budgets, CMOs should heed the following issues that clients take into account when considering outsourcing manufacturing:
    • Establishing a good working relationship;
    • Complying with the client’s quality standards;
    • Offering a secure supply (control of capacity);
    • Protecting intellectual property; and
    • Sticking to a schedule.
    What are CMOs spending their budgets on?
    Biotherapeutic developers aren’t the only ones with budgets, obviously. To see how contract manufacturers’ own budgets are trending, we isolated CMO respondents from our sample and analyzed the data.

    The results show that hiring and equipment are important budget areas for CMOs this year. The largest increase is pegged for hiring new operations staff, while spending on hiring of new scientific staff is also expected to see double-digit growth.

    Sandwiched in between, CMOs, as with biotherapeutic developers, are also earmarking large increases for new capital equipment, as virtually all the CMOs we surveyed will be increasing their spending on this area to at least some degree.

    Not far behind, CMOs are hiking their spending on new technologies to improve efficiencies and costs for downstream production. This appears to be a greater budget focus than upstream innovation, although many are nonetheless also increasing their spending in this area.

    It’s not too surprising that downstream innovation is a key budget area for CMOs. In fact, downstream processing advances rank as their third-most important biomanufacturing trend, behind only manufacturing productivity/efficiency and continuous bioprocessing. Not surprisingly, given the emphasis that CMOs place on single-use/disposables—it is disposable purification technologies that top the list of innovation that CMOs want their suppliers to develop first, of the 23 innovative areas identified.

    Other specific downstream advances that CMOs wish to spend their budgets on this year, and where they are actively considering for production issues or problems include:
    • In-line buffer dilution systems;
    • Single-use disposable TFF membranes;
    • Single-use pre-packed columns; and
    • Use of high capacity resins.
    The presence of single-use devices is to be expected give that, when asked what they’ve done in the past 12 months to improve downstream purification operations, CMOs were most likely to say that they’ve investigated single-use disposable downstream devices.

    Meanwhile, the increased spending on hiring makes sense in light of the emphasis that CMOs place on staffing to avoid future capacity constraints. Indeed, 4 of the top 5 areas that CMOs believe will likely create future capacity constraints relate to the inability to hire and/or retain experienced scientific, technical and production staff.

    Conclusion
    The spending climate for outsourced biopharmaceutical manufacturing is changing. This year’s increase in budgets for outsourcing, at 2.4%, is well below the hikes seen in previous years. This slowdown in budget growth has occurred parallel to an increase in budgets for in-house manufacturing, suggesting that the tide may be gradually turning away from the outsourcing expansion of recent years and back towards a maximization of in-house resources and capabilities.

    Among CMOs themselves, there appears to be quite an appetite for increased spending, likely driven by the expansion of the outsourcing market in recent years, which has been driven in part by the advent of biosimilars. CMOs are earmarking large increases for new operations and scientific staff, separately acknowledging that process development staff—both upstream and downstream—are proving to be the job positions they are finding most difficult to fill.

    New capital equipment and innovative technologies are also slated for budget increases for CMOs. With contract manufacturers typically taking the lead in adopting innovative technologies, our data indicates that trends continue to favor their investment in single-use disposable devices. With downstream advances on the agenda this year, disposable purification equipment is likely to be near the top of the list for CMOs.

    With competition increasing among CMOs, they’ll be spending to secure the best staff and the newest technologies to offer as differentiators in order to win business.


    Eric S. Langer
    BioPlan Associates

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports.  elanger@bioplanassociates.com  301-921-5979.  www.bioplanassociates.com
    Related Searches
    • Biomanufacturing
    • Process Development
    • Outsourcing
    • contract manufacturing organizations
    Suggested For You
    Lessons Learned: Choosing and Managing a CDMO Lessons Learned: Choosing and Managing a CDMO
    The Ever-Evolving World of Combination Products The Ever-Evolving World of Combination Products
    Embedding Your Drug Strategy Within a Solid Foundation for Success Embedding Your Drug Strategy Within a Solid Foundation for Success
    Sepha Launches Small Batch Contract Packaging Service Sepha Launches Small Batch Contract Packaging Service
    A Potential “Marriage” A Potential “Marriage”
    Injectables Firms Expand Capacity Injectables Firms Expand Capacity
    TFF Expands Engagement with Experic TFF Expands Engagement with Experic
    India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines
    The Pandemic’s Become an Insurmountable Opportunity The Pandemic’s Become an Insurmountable Opportunity
    Vetio Animal Health Vetio Animal Health
    Current Trends in Analytical Testing Current Trends in Analytical Testing
    CMOs & Biosimilars Mfg. in the U.S. CMOs & Biosimilars Mfg. in the U.S.
    PBOA Praises Action On FDA Reauthorization  PBOA Praises Action On FDA Reauthorization
    Adents, Microsoft Present Serialization Solution Adents, Microsoft Present Serialization Solution
    CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges

    Related Columns

    • Biosimilars
      The Bioprocessing Trek

      The Bioprocessing Trek

      Biosimilars are the next speed-bump for CMOs
      Emil W. Ciurczak, DoraMaxx Consulting 09.16.19

    • Biosimilars
      Know the Challenges of  Biosimilar Manufacturing

      Know the Challenges of Biosimilar Manufacturing

      Best practices for a competitive market
      Jerry Martin and Michiel Ultee 09.06.17

    • Biosimilars
      Indian Generic Firms  Expand Biosimilar Portfolios

      Indian Generic Firms Expand Biosimilar Portfolios

      With more players entering the ring, the race to enter the promising biosimilars market is getting hotter by the day in India
      S. Harachand, Contributing Editor 05.09.17


    • Biosimilars
      CMOs & Biosimilars Mfg. in the U.S.

      CMOs & Biosimilars Mfg. in the U.S.

      Biosimilars are moving from novel opportunity to mainstream product
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.20.17

    • Biosimilars

      Biosimilars Update

      Fulfilling a dire need, but at what (human) cost?
      Ben Locwin, Contributing Editor 04.03.17

    • Biosimilars | Clinical Trials | Drug Discovery | Process Development

      Like the Temperature, It Feels Like Deal Activity is Heating Up

      A summary of 2016 transactions so far
      Chad Moore, Leerink Partners LLC 05.05.16


    • Biosimilars | Clinical Trials

      Outsourced Pharma Services: 2015 Review & 2016 Outlook

      ...
      Chad Moore, Leerink Partners 01.28.16

    • APIs | Biosimilars | Clinical Trials | Process Development | Vials

      2015 in Review: 6 Key Trends Affecting CMOs

      A look at major CMO trends ranging from budgets to growth opportunities
      Eric S. Langer, BioPlan Associates 11.17.15

    • APIs | Biosimilars

      API and Intermediate Outsourcing Trends

      One thing’s for sure, when it comes to pharma trends there is no definitive trend
      Ben Locwin, Healthcare Science Advisors 10.07.15


    • Biosimilars | Fill/Finish | QA/QC

      CMOs Are Willing to Pay for More Innovation

      Downstream improvements top the list
      Eric S. Langer, BioPlan Associates 09.11.15

    • Analytical Services | APIs | Bioanalytical Services | Biosimilars | Chemistry | Clinical Trials | Excipients | GMPs/GCPs | Laboratory Testing | Microbiology | QA/QC | R&D | Regulatory Affairs | Supply Chain | Toxicology | Validation

      Inventas vitam iuvat excoluisse per artes (Let us improve life through science and art)

      But Qui bono? (Who benefits?)
      Emil W. Ciurczak, DoraMaxx Consulting 07.14.15

    • Biosimilars | GMPs/GCPs | Inspections | Regulatory Affairs

      Biosimilars and Their Future in Medicine

      The first step is understanding what biosimilars actually are
      Ben Locwin, Healthcare Science Advisors 06.02.15


    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Logistics | Lyophilization | Methods Development | Process Development | QA/QC | Serialization | Supply Chain | Validation

      CMOs Facing Significant Capacity Constraints

      Downstream purification creating chronic problems
      Eric S. Langer, BioPlan Associates 06.02.15

    • Biosimilars | Methods Development | Process Development | Supply Chain | Validation

      CMOs Demanding Easier-to-Integrate Single-use Devices

      Disposables’ implementation and integration critical; suppliers being put on notice
      Jean-Claude Lupis and Eric S. Langer, BioPlan Associates 05.06.15

    • APIs | Biosimilars | Process Development | Supply Chain

      Biosimilars Improving Efficiency, Cost for All Biologics

      ...
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.01.15

    Trending
    • Franco Negron Named CEO Of ApiJect Systems America
    • Obituary Notice: Russell “Russ” Haines
    • Resilience Acquires Ology Bioservices
    • Johnson & Johnson 1Q Results
    • RDIF, Hualan Ink COVID-19 Vaccine Deal
    Breaking News
    • Nanoform, Aprecia Partner to Advance 3DP Nanomedicines
    • KemPharm Receives $10M Milestone for FDA Approval of Azstarys
    • Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax
    • Syneos, Medable Partner for New Decentralized Capabilities
    • CSafe Global Appoints SVP of Technology and Innovation
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Ashland Supports the Nature Conservancy Forest Restoration Effort to Help Plant a Billion Trees
    Martin Bauer Announces Installation of Agile Filling System at Bethlehem, PA Facility
    PepsiCo and Ingredion Begin Pilot Partnership with Soil and Water Outcomes Fund
    Coatings World

    Latest Breaking News From Coatings World

    AkzoNobel Shareholders Approve Final Dividend at Annual General Meeting
    PPG Maintains EcoVadis Gold Rating
    Sustainable Plastics Will Make Up More Than 15% of Production by 2030
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Getinge Receives FDA Clearance for Multiple Products
    Study Shows Benefits of CCHD Screening Using Masimo SET Pulse Oximetry
    TEAM Technologies Acquires ViruDefense
    Contract Pharma

    Latest Breaking News From Contract Pharma

    RDIF, Minapharm to Make Over 40M Doses of the Sputnik V Vaccine in Egypt
    Bora Pharmaceuticals Completes Health Canada Inspection
    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Knoll Printing & Packaging Commits to a Healthy Ocean and Planet
    New Sustainable Jar from APC Packaging
    Qosmedix Launches Corporate Social Responsibility Initiative
    Happi

    Latest Breaking News From Happi

    Multi-Purpose Sustainable 'Just Add Water' Household Cleaner Expands Cleaning Products
    Kao Launches Oribe in Japan
    Love Beauty and Planet Shares Sustainability Initiatives With Refillable Hair Care at Target
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    SE-DA Invests in Kornit Presto S
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Epson upgrades SurePress demo facility
    Xeikon helps converters navigate toner and inkjet
    Mactac introduces Simply Sustainable initiative
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Savaré Strengthens Technical Support for the Americas
    FiberVisions, Avgol Partner with Polymateria
    High-Tech Conversions Launches Wipes Dispenser
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Clears Orthofix's 3D-Printed FORZA Titanium TLIF Spacer System
    Patients Conclude Clinical Visits in Knee Osteoarthritis Treatment Study
    SeaSpine Begins Limited Rollout of WaveForm TO 3D-Printed Interbodies
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Identiv, Ameta International Announce US, Canadian Distribution Partnership
    Adesis Achieves ISO 9001:2015 Certification
    Louis Widmer SA Complies with EU Anti-Counterfeiting Directive with Zebra Technologies’ Solution

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login